Lymphangioleiomyomatosis (LAM) · line 1 · Sirolimus monotherapy (progressive LAM)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-SIROLIMUS-LAM |
| ID | IND-LAM-1L-SIROLIMUS |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-LAM |
| Sources | SRC-MILES-MCCORMACK-2011 |
Notes
STUB — pending Clinical Co-Lead sign-off. Only FDA/EMA-approved therapy for LAM. Effect is disease-stabilizing; discuss realistic expectations. Sirolimus registered in Ukraine for transplant indication — off-label use for LAM requires clinical justification. VEGF-D ≥800 pg/mL both confirms diagnosis and tracks response.
Used By
Algorithms
ALGO-LAM-1L- ALGO-LAM-1L